A Study of the Novel Drug Dimebon in Patients With Huntington's Disease
NCT ID: NCT00497159
Last Updated: 2015-06-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
91 participants
INTERVENTIONAL
2007-07-31
2008-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety Study of the Novel Drug Dimebon to Treat Patients With Huntington's Disease
NCT00387270
A Safety and Efficacy Study of Dimebon in Patients With Huntington Disease
NCT00920946
An Extension of the HORIZON Protocol Evaluating the Safety of Dimebon (Latrepirdine) in Subjects With Huntington Disease
NCT01085266
A Phase II Safety and Tolerability Study With SEN0014196
NCT01521585
A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease
NCT06585449
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Placebo
Placebo
Placebo TID x 90 days
2
Dimebon
Dimebon
Dimebon 20 mg TID x 90 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Placebo
Placebo TID x 90 days
Dimebon
Dimebon 20 mg TID x 90 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Able to take medication (capsules) by mouth.
Exclusion Criteria
* Females who are pregnant or lactating or who intend to become pregnant during the study period.
29 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Huntington Study Group
NETWORK
Medivation, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Karl Kieburtz, MD, MPH
Role: PRINCIPAL_INVESTIGATOR
Huntington Study Group, University of Rochester
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Huntington Study Group
Rochester, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Kieburtz K, McDermott MP, Voss TS, Corey-Bloom J, Deuel LM, Dorsey ER, Factor S, Geschwind MD, Hodgeman K, Kayson E, Noonberg S, Pourfar M, Rabinowitz K, Ravina B, Sanchez-Ramos J, Seely L, Walker F, Feigin A; Huntington Disease Study Group DIMOND Investigators. A randomized, placebo-controlled trial of latrepirdine in Huntington disease. Arch Neurol. 2010 Feb;67(2):154-60. doi: 10.1001/archneurol.2009.334.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DIM05
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.